Figure 2

Figure 2

Validation of selected PKIS hit compounds. (A) The efficacy of the PKIS hit compounds against intracellular MRSA was determined by CFU count and given as the percentage of the DMSO control. (B–F) The efficacy of GSK2008607A, GW296115X and GW633459 on the bacterial burden of MRSA-infected HeLa cells (B, n=17), MelJuSo cells (C, n=7), A549 cells (D, n=7), MCF7 cells (E, n=7) and PMA-differentiated THP-1 cells (F, n=6) was determined by CFU count. (G–K) The effect of the compounds on cell viability was assessed using LDH-release assay for HeLa cells (G), MelJuSo cells (H), A549 cells (I), MCF7 cells (J) and PMA-differentiated THP-1 cells (K). Bars and error bars show the median ± interquartile range. Each datapoint represents the results of an independent experiment. Statistical significance of observed differences was tested in comparison to the DMSO controls using Friedman tests (*p < 0.05; **p < 0.01; ***p < 0.001).